Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shaw Leaves Lilly To Helm Gilead’s Kite

Executive Summary

After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.

Advertisement

Related Content

Gilead To Let Kite Fly Free; O’Day Says It Will Become Separate Business Unit
Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures
Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Lilly's New Year Resolution: Make New Launches Into Blockbusters
A Q&A With Lilly Biomedicines President Christi Shaw
Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125528

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel